Phil Rivers Technology Secures IND Approval for PR00012 from NMPA’s CDE
Beijing-based Phil Rivers Technology Co.,Ltd, a high-tech platform company incubated by the Institute of Computing...
Hansoh Pharmaceutical’s Ameile Receives NMPA Review for Fifth Indication in NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that its fifth indication filing...
China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...
Genesis RMN Robotic Magnetic Navigation System Approved by China’s NMPA
The Genesis RMN cardiac electrophysiological robot magnetic navigation system, represented in China by Shanghai Microport...
GSK plc Receives EC Approval for Single-Vial Menveo Vaccine for Meningococcal Disease
GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European...
TenNor Therapeutics Partners with Grand Life Sciences for Rifasutenizol Commercialization in China
China-based TenNor Therapeutics has entered into an exclusive commercialization cooperation agreement with compatriot firm Grand...
Immunochina Pharmaceuticals’ IM19 CAR-T Therapy Accepted for Review by NMPA
Beijing-based biotech company Immunochina Pharmaceuticals has announced that the National Medical Products Administration (NMPA) has...
Thederma’s TAP-1503 Cream Approved by China’s NMPA for Atopic Dermatitis Treatment
China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National...
Novartis’s Kisqali Approved by EC for Adjuvant Treatment of High-Risk Early Breast Cancer
Swiss pharmaceutical company Novartis (NYSE: NVS) has announced that it has received marketing approval from...
Sanofi Launches Modulus, a Pioneering Manufacturing Facility in Singapore
Global healthcare company Sanofi (NASDAQ: SNY) has inaugurated Modulus, its state-of-the-art manufacturing facility in Singapore....
Chia Tai Tianqing’s Benmelstobart Combo Approved by NMPA for Endometrial Cancer Treatment
China-based Chia Tai Tianqing has announced that the National Medical Products Administration (NMPA) has granted...
Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a China-based biopharmaceutical company, has received market approval...
NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...
CORXEL’s Varenicline Nasal Spray Approved by NMPA for Dry Eye Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has received approval...
Arrowhead and Sarepta Seal $11.38 Billion Global Licensing Deal for Rare Disease Treatments
US-based companies Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) and Sarepta Therapeutics (NASDAQ: SRPT) have announced a...
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China...
Roche’s Evrysdi Receives Patent Term Extension in China, Extending Protection to 2035
The China National Intellectual Property Administration (CNIPA) has granted Swiss pharmaceutical giant Roche (SWX: ROG)...
CanSino Biologics’ Menhycia Vaccine Aims to Expand Age Range with NMPA Filing
CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted...
Jiangsu Hengrui Medicine’s SHR-1819 Receives NMPA Approval for Atopic Dermatitis Clinical Trial
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received clinical trial...
AstraZeneca’s Truqap Meets Primary Endpoint in Phase III Prostate Cancer Study
UK-based pharmaceutical giant AstraZeneca Inc., (AZ, NASDAQ: AZN) has announced that its Phase III CAPItello-281...